Entacapone is an inhibitor of catechol-O-methyltransferase (COMT) and is indicated as an adjunct treatment for patients taking levodopa and carbidopa for Parkinson’s Disease who experience the signs and symptoms of end-of-dose “wearing-off”.
| Reasons taken |
# of patients
Efficacy
|
Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Parkinson's Disease PD | 108 |
|
|
|
|
12 | |
| Support another treatment | 15 |
|
|
|
6 | ||
| Wearing off effect | 8 | 0 | |||||
| Stiffness/Spasticity | 7 |
|
|
2 | |||
| Other | 6 |
|
2 | ||||
| increase sinemet effect | 5 |
|
1 |
See all 171 patients currently taking Entacapone
Mouse over the table for more information
Top 10 dosages based on patients currently taking Entacapone. See all 20 dosages ►
| 200 mg all the time (24/7) | 200 mg as needed | 200mg as needed | daily | 1 mg daily | 20 mg daily | 100 mg daily | 200 mg daily | 250 mg daily | 300 mg daily | 400 mg daily | 500 mg daily | 600 mg daily | 800 mg daily | 900 mg daily | 1000 mg daily | 1200 mg daily | 1400 mg daily | 1600 mg daily | 8200 mg daily | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2
|
1
|
2
|
6
|
1
|
1
|
1
|
25
|
1
|
6
|
11
|
1
|
38
|
36
|
1
|
20
|
11
|
2
|
5
|
1
|
||
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Side effects too severe
|
12 | 36% |
|
|
Did not seem to work
|
8 | 24% |
|
|
Doctor's advice
|
8 | 24% |
|
|
Other
|
7 | 21% |
|
|
Expense
|
3 | 9% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on March 22, 2010.